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ABSTRACT 
Review on Down syndrome, with data on clinics, 
susceptibility to neoplasms, and the genes involved 
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Etiology 
 Down syndrome (DS) has an incidence of 
approximately 1 in 700 live births, and is the most 
common aneuploidy of the autosomal chromosomes. 
 Down syndrome is caused by an extra copy of 
chromosome 21.  Most cases (95%) are the result of 
nondisjunction, leading to three free copies of the 
chromosome; this nondisjunction usually occurs in 
maternal meiosis I, though maternal meiosis II and 
paternal meiosis II errors also do occur.  There is an 
increased risk of this nondisjunction with increased 
maternal age. 
 Another 4% of cases are the result of an extra copy 
of chromosome 21 transmitted by translocation with 
an acrocentric chromosome (usually chromosome 14 
or 21).  These translocations may be present in the 
parent who has a balanced translocation such as 
t(14;21) or t(21;21), and represent a genetic risk of 
inheritance.  However, most of the translocations 
occur de novo. 
 The remaining cases are usually due to mosaicism 
for trisomy 21 with a normal karyotype.  These 
patients tend to have less severe phenotypes 
Clinics 
Phenotype and clinics 
Many organ system abnormalities are associated 
with Down syndrome (DS): 
 Craniofacial dysmorphism:  Most children are 
brachycephalic with a relatively flat occiput.  They 
may have microcephaly with upslanting palpebral 
fissures, small noses, flat nasal bridge, inner 
epicanthal folds, hypertelorism, and small ears. 
 Central nervous system:  Intellectual disabilities 
are present in most patients.  Alzheimer disease 
develops in more than half of DS patients by the age 
of 60 years. 
 Cardiovascular:  Endocardial cushion defects lead 
to atrioventricular defects (most common), with less 
common ventricular septal defects, atrial septal 
defects, and tetralogy of Fallot. 
 Respiratory:  Some respiratory disorders include 
upper respiratory tract anomalies, obstructive sleep 
apnea, recurrent aspiration, and recurrent respiratory 
tract infections. 
 Hematologic:  Individuals with DS often have an 
immunodeficiency, leading to increased risk of 
infection.  Newborns have an increased risk of 
transient abnormal myelopoiesis, and children and 
young adults especially those between 1 and 5 years 
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of age have a marked increased risk of leukemia (see 
below under Neoplastic Risk). 
 Gastrointestinal:  Duodenal atresia/stenosis, 
Hirschsprung disease, esophageal atresia, pyloric 
stenosis, and imperforate anus are identified in some 
DS patients. 
 Endocrine:  Hypothyroidism often occurs in 
neonates.  In older patients, hyper- or hypo-
thyroidism may be present with or without diabetes 
mellitus. 
 Musculoskeletal:  Hypotonia is present in many.  
Ligament laxity, including occipitocervical 
instability and atlantoaxial instability are also 
common.  Joints may be hyperflexible.  Hands can 
be notable for short metacarpals and phalanges 
and/or a single palmar transverse (Simian) crease.  
Fifth finger hypoplasia may also be present.  Feet 
may demonstrate a wide gap between the first and 
second toes.  Talipes equinovarus may also occur. 
 Eye/vision:  Severe refractive errors are present in 
approximately half of the patients. 
 Hearing:  Conductive, mixed, or neurosensory 
hearing loss is common. 
 Oral:  DS patients may have macroglossia, with 
microdontia 
Neoplastic risk 
 Those with Down syndrome have a decreased risk 
of most solid tumors.  Exceptions include testicular 
cancer, including germ cell tumors.  The risk of 
extragonadal and ovarian germ cell tumors is also 
reportedly increased in DS (Nizetic and Groet, 2012; 
Englund et al., 2013). 
 Transient abnormal myelopoiesis (TAM) is thought 
to occur in up to 30% of neonates with Down 
syndrome. Symptomatic in up to 10%, this disorder 
is characterized by increased blasts (usually 
megakaryoblasts) which can lead to hepatomegaly, 
splenomegaly, and respiratory distress.  In these 
patients, somatic GATA1 gene mutations are present 
in the clonal population.  TAM presents within the 
first 7 days of life and usually spontaneous resolves 
within 2-3 months.  Some infants who are 
symptomatic may require chemotherapy. 
 The risk of acute myeloid leukemia in children with 
DS is 150 times greater than in the general 
population; the incidence of acute megakaryoblastic 
leukemia is 500 times more likely in the DS 
population (Creutzig et al., 1996; Hasle et al., 2000).  
This myeloid leukemia of Down syndrome (ML-DS) 
occurs between 1 and 4 years of age, with 16-30% of 
children also having a history of clinical TAM. 
Somatic mutations in GATA1 are also identified in 
ML- DS. 
 The risk of acute lymphoblastic leukemia (ALL) in 
DS is also elevated, estimated at 40 times greater in 
children aged 1-5 years with DS compared to those 
without DS of the same age (Hasle et al., 2000). 
Unlike those without DS, ALL in DS usually does 
not have the classic favourable or unfavourable 
cytogenetic abnormalities. These ALL of DS cases 
do often have CRFL2 gene rearrangements either 
with P2RY8, also in the pseudoautosomal region of 
Xp22.33/Yp11 ( del(X)(p22.33p22.33) or 
del(Y)(p11.32p11.32)), or with IGH 
(immunoglobulin heavy chain locus), on 14q32 ( 
t(X;14)(p22;q32) or t(Y;14)(p11;q32)) (Mullighan 
et al., 2009; Hertzberg et al., 2010). JAK2 activating 
mutations are present in approximately 20% of ALL 
of DS cases, usually with mutations at R683 in the 
pseudokinase domain (Bercovich et al., 2008; 
Kearney et al., 2009; Gaikwad et al., 2009).  IKZF1 
deletions are also often identified in ALL of DS 
(Hertzberg et al., 2010; Buitenkamp et al., 2012). 
Treatment 
 Most cases of TAM (66-84%) will spontaneously 
resolve without the need for interventions 
(Klusmann et al., 2008; Gamis et al., 2011). 
Cytarabine (cytosine arabinose) may be employed in 
infants with life-threatening symptoms (Massey et 
al., 2006) 
 ML-DS requires chemotherapy, though at a reduced 
intensity compared to those without Down 
syndrome. 
 Those with ALL of DS are treated similarly to those 
with ALL without DS.  These patients have an 
increased susceptibility and toxicity to methotrexate. 
Evolution 
 The majority of DS patients with TAM will have 
spontaneous resolution without treatment within 2-3 
months; however, 16-30% of infants may go on to 
develop ML-DS (Klusmann et al., 2008). 
 For Down syndrome patients in general, 
Alzheimer's disease develops in more than half by 60 
years of age. 
Prognosis 
 The mortality rate for TAM is approximately 15-
20%, though approximately half of these deaths are 
related to other congenital abnormalities of Down 
syndrome (Klusmann et al., 2008; Gamis et al., 
2011). 
 ML-DS has a better prognosis than myeloid 
leukemia without Down syndrome.  However, these 
individuals are still at a high risk for infection-related 
deaths.  (Lange et al., 1998; Gamis et al., 2003; Rao 
et al., 2006) 
 Compared to those with ML-DS, ALL of DS has an 
equivalent to poorer prognosis compared to those 
with ALL without DS.  Some studies have shown 
increased induction failures, higher relapse rates, and 
increased therapy-related mortality in those with 
ALL of DS. 
 For Down syndrome in general, the median age of 
mortality has increased throughout the years, most 
recently reported at almost 60 years (Englund et al., 
2013).  The most common causes of death are 
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infectious diseases (mostly pneumonia), congenital 
malformations (such as heart defects), circulatory 
disease, and dementia (Englund et al., 2013). 
References 
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, 
Taub JW, Ravindranath Y, Dahl G, Weinstein HJ. A 
prospective study of the natural history of transient leukemia 
(TL) in neonates with Down syndrome (DS): Children's 
Oncology Group (COG) study POG-9481. Blood. 2006 Jun 
15;107(12):4606-13 
Antonarakis SE. Down syndrome and the complexity of 
genome dosage imbalance. Nat Rev Genet. 2017 
Mar;18(3):147-163 
Arumugam A, Raja K, Venugopalan M, Chandrasekaran B, 
Kovanur Sampath K, Muthusamy H, Shanmugam N. Down 
syndrome-A narrative review with a focus on anatomical 
features. Clin Anat. 2016 Jul;29(5):568-77 
Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, 
Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, 
Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann 
G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, 
Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal 
NB, Green AR, Izraeli S. Mutations of JAK2 in acute 
lymphoblastic leukaemias associated with Down's 
syndrome Lancet. 2008 Oct 25;372(9648):1484-92. 
Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, 
Meijerink JP, Beverloo HB, Zimmermann M, de Haas V, 
Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, 
Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, 
den Boer ML, Zwaan CM. Outcome in children with Down's 
syndrome and acute lymphoblastic leukemia: role of IKZF1 
deletions and CRLF2 aberrations Leukemia. 2012 
Oct;26(10):2204-11. 
Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, 
Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J. 
Myelodysplasia and acute myelogenous leukemia in 
Down's syndrome. A report of 40 children of the AML-BFM 
Study Group. Leukemia. 1996 Nov;10(11):1677-86. 
Englund A, Jonsson B, Zander CS, Gustafsson J, Annerén 
G. Changes in mortality and causes of death in the Swedish 
Down syndrome population Am J Med Genet A. 2013 
Apr;161A(4):642-9 
Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, 
Izraeli S, Plon SE, Basso G, Pession A, Rabin KR. 
Prevalence and clinical correlates of JAK2 mutations in 
Down syndrome acute lymphoblastic leukaemia Br J 
Haematol. 2009 Mar;144(6):930-2 
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, 
Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, 
Massey G, Perentesis J, Ravindranath Y, Taub J, Smith 
FO.. Natural history of transient myeloproliferative disorder 
clinically diagnosed in Down syndrome neonates: a report 
from the Children's Oncology Group Study A2971. Blood. 
2011 Dec 22;118(26):6752-9 
Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, 
Barnard DR, Gold S, Smith FO; Children's Cancer Group 
Study 2891.. Increased age at diagnosis has a significantly 
negative effect on outcome in children with Down syndrome 
and acute myeloid leukemia: a report from the Children's 
Cancer Group Study 2891. J Clin Oncol. 2003 Sep 
15;21(18):3415-22 
Hasle H, Clemmensen IH, Mikkelsen M.. Risks of leukaemia 
and solid tumours in individuals with Down's syndrome 
Lancet. 2000 Jan 15;355(9199):165-9 
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, 
Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, 
Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, 
Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich 
D, Borkhardt  A, Kempski H, te Kronnie G, Bourquin JP, 
Domany E, Izraeli S. Down syndrome acute lymphoblastic 
leukemia, a highly heterogeneous disease in which aberrant 
expression of CRLF2 is associated with mutated JAK2: a 
report from the International BFM Study Group Blood. 2010 
Feb 4;115(5):1006-17. 
Kearney L, Gonzalez De Castro D, Yeung J, Procter J, 
Horsley SW, Eguchi-Ishimae M, Bateman CM, Anderson K, 
Chaplin T, Young BD, Harrison CJ, Kempski H, So CW, 
Ford AM, Greaves M. Specific JAK2 mutation (JAK2R683) 
and multiple gene deletions in Down syndrome acute 
lymphoblastic leukemia Blood. 2009 Jan 15;113(3):646-8. 
Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, 
Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, 
Reinhardt D.. Treatment and prognostic impact of transient 
leukemia in neonates with Down syndrome. Blood. 2008 
Mar 15;111(6):2991-8. 
Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley 
JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, 
Woods WG.. Distinctive demography, biology, and outcome 
of acute myeloid leukemia and myelodysplastic syndrome 
in children with Down syndrome: Children's Cancer Group 
Studies 2861 and 2891. Blood. 1998 Jan 15;91(2):608-15. 
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin 
MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, 
Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, 
Cheng J, Heerema  NA, Basso G, Pession A, Pui CH, 
Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin 
KR. Rearrangement of CRLF2 in B-progenitor- and Down 
syndrome-associated acute lymphoblastic leukemia Nat 
Genet. 2009 Nov;41(11):1243-6 
Ni&cacute;eti? D, Groet J. Tumorigenesis in Down's 
syndrome: big lessons from a small chromosome. Nat Rev 
Cancer. 2012 Oct;12(10):721-32 
Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann 
IM, O'Marcaigh A, Wheatley K, Webb DK. Treatment for 
myeloid leukaemia of Down syndrome: population-based 
experience in the UK and results from the Medical Research 
Council AML 10 and AML 12 trials. Br J Haematol. 2006 
Mar;132(5):576-83 
This article should be referenced as such: 
Chisholm KM. DownSyndrome. Atlas Genet 
Cytogenet Oncol Haematol. 2018; 22(4):182-184. 
